Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2008

View Archived Issues

Novel antibacterial agents reported in recent patent literature

Recent patents disclose new compounds for treating cancer

Neurogen suspends phase II/III insomnia study of adipiplon

Erythropoietin shows benefits for motoneuron degeneration treatment in preclinical studies

A novel positive allosteric modulator of nAChR7 under preclinical development for schizophrenia

European Commission grants orphan designation to Marqibo for ALL

Abraxis receives approval to market Abraxane for breast cancer in China

Amgen presents positive top-line denosumab results from phase III pivitol trial

Clinical results from blonanserin for the treatment of cognitive deficits in schizophrenia

Medarex provides updates on antibody development

Cardiome reports positive phase IIb data for oral vernakalant

FDA approves OncoGenex's SPA for phase III trial of OGX-011 in HRPC

NanoViricides reports excellent efficacy of EKC-Cide in first animal study

ValiRx to acquire Cronos Therapeutics

Edison's second-generation coenzyme Q10 analogue enters phase I clinical trials

Moderate efficacy of ARG-201 in patients with late-phase systemic sclerosis / News in Context

Luminex and ViroNovative sign license agreement for human metapneumovirus rights

Map commences phase III MAP-0004 trial in patients with migraine

Theravance presents clinical results from its LAMA Respiratory Program

FDA accepts Genta's amendment to NDA for Genasense in CLL as complete response

MRC and Biolex successfully complete collaboration to humanize BLX-301

Immunomedics enters worldwide license agreement with Nycomed for veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...